Padagis (PRIVATE.PADAGIS)

Overall impact
D (33)

Commentary

Padagis is a below-average overall performer. With a 'D' rating of 33.5 for overall impact (bottom 25% of all companies), Padagis ranks 161st out of 164 industry peers, behind BridgeBio Pharma, HOOKIPA Pharma, cbdMD and 157 others, and ahead of Endo International, Taro Pharmaceutical, and Curaleaf. On top material causes for Padagis's industry (Pharmaceuticals), Padagis performs well in Child and Maternal Health (83.4 score) and Technology Innovation (88.6) and performs poorly in Accountable Institutions (12.0 score), Fair Labor Practices (16.5), Improved Mental Health (25.1) and 9 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.PADAGIS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2004
Employees
1,300
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Michigan, United States
Share classes
PRIVATE.PADAGIS
Description
Manufacturer and supplier of pharmaceutical products with a focus on dermatological products across the United States and Israel. The company offers topical generic medicines in multiple dosage forms, including creams, foams, mousses, gels, liquids and inhalable products, enabling patients and health systems to treat ailments at more affordable prices.
Material causes
Ethos considers the following causes material for Padagis, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.